TITLE:
Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease

CONDITION:
Gaucher's Disease

INTERVENTION:
glucocerebrosidase

SUMMARY:

      OBJECTIVES:

      I. Evaluate the efficacy and toxicity of glucocerebrosidase enzyme therapy in patients with
      Gaucher disease.
    

DETAILED DESCRIPTION:

      PROTOCOL OUTLINE:

      Patients are treated with intravenous glucocerebrosidase every 2 weeks. The dose is based on
      clinical severity of disease and response to therapy.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to 65 Years
Criteria:

        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Gaucher disease with glucocerebrosidase deficiency confirmed
        by enzymatic or molecular assay At least 3 organ systems affected, based on the following
        criteria: Anemia Thrombocytopenia Organomegaly Bone deterioration on radiograph Pulmonary
        compromise Symptoms compromise daily activities or risk longevity No neurologic disease
      
